SHP2 and UGP2 are biomarkers for progression and poor prognosis of gallbladder cancer
Q Wang, Z Yang, Q Zou, Y Yuan, J Li, L Liang… - Cancer …, 2016 - Taylor & Francis
Q Wang, Z Yang, Q Zou, Y Yuan, J Li, L Liang, G Zeng, S Chen
Cancer investigation, 2016•Taylor & FrancisBiomarkers for the diagnosis, prognosis, and targeting therapy of gallbladder cancers are
not clinically available. This study demonstrated that the percentage of cases with positive
SHP2 and UGP2 expression significantly correlated with the percentage of cases with
positive vimentin, β-catenin, MMP2, MMP9, and Ki-67 expression, large tumor size, high
TNM stage, lymph node metastasis, and survival in patients with adenocarcinomas and
squamous cell/adenosquamous carcinomas. Positive SHP2 and UGP2 expression are …
not clinically available. This study demonstrated that the percentage of cases with positive
SHP2 and UGP2 expression significantly correlated with the percentage of cases with
positive vimentin, β-catenin, MMP2, MMP9, and Ki-67 expression, large tumor size, high
TNM stage, lymph node metastasis, and survival in patients with adenocarcinomas and
squamous cell/adenosquamous carcinomas. Positive SHP2 and UGP2 expression are …
Abstract
Biomarkers for the diagnosis, prognosis, and targeting therapy of gallbladder cancers are not clinically available. This study demonstrated that the percentage of cases with positive SHP2 and UGP2 expression significantly correlated with the percentage of cases with positive vimentin, β-catenin, MMP2, MMP9, and Ki-67 expression, large tumor size, high TNM stage, lymph node metastasis, and survival in patients with adenocarcinomas and squamous cell/adenosquamous carcinomas. Positive SHP2 and UGP2 expression are independent poor-prognostic factors in both types of tumors. Our study suggested that positive SHP2 and UGP2 expression correlated with clinicopathological and biological behaviors, and poor-prognosis of gallbladder cancer.
Taylor & Francis Online